Considerable changes have occurred in the management of differentiated thyroid cancer
(DTC) during the past four decades, based on improved knowledge of the biology of DTC …

Recurrent, metastatic disease represents the most frequent cause of death for patients with
thyroid cancer, and radioactive iodine (RAI) remains a mainstay of therapy for these patients …

Thyroid cancer is the most common endocrine malignancy. Most thyroid cancer types
respond well to conventional treatment consisting of surgery and radioactive iodine (RAI) …

Background Lenvatinib is a multikinase inhibitor approved to treat radioiodine-refractory
differentiated thyroid cancer (RR-DTC) at a starting dose of 24 mg/day. This study explored …

In the 9 years since the publication of our 2011 review of targeted treatment of thyroid cancer
with multikinase inhibitors, much has changed in the landscape of this heterogeneous …

Differentiated thyroid cancers (DTC) are commonly and successfully treated with total
thyroidectomy plus/minus radioiodine therapy (RAI). Medullary thyroid cancer (MTC) is only …

Based on experimental data, the inhibition of the MAPkinase pathway in patients with
radioiodine-refractory thyroid cancer was capable of inducing a redifferentiation. Preliminary …

Objective Selpercatinib is a highly selective RET-inhibitor drug, approved for the treatment of
RET-altered lung and thyroid cancers. So far, RET-altered medullary thyroid cancer (MTC) …

Simple Summary In the last decades, many researchers produced promising data
concerning genetics and tumor microenvironment of poorly differentiated thyroid cancer …

Patients with thyroid cancer (TC) usually have an excellent prognosis; however, 5–10% of
them develop an advanced disease. The prognosis of this subgroup is still favourable if the …